Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients

Published:2019-04-01 Issue:9 Volume:49 Page:1181-1187
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Pouillon Lieven¹²,Danese Silvio³^ORCID,Hart Ailsa⁴,Fiorino Gionata³,Argollo Marjorie³⁵,Selmi Carlo³,Carlo-Stella Carmelo³,Loeuille Damien¹,Costanzo Antonio³,Lopez Anthony¹^ORCID,Vegni Elena³,Radice Simona³,Gilardi Daniela³,Socha Marie¹,Fazio Maria³,González-Lorenzo Marien³,Bonovas Stefanos³^ORCID,Magro Fernando⁶^ORCID,Peyrin-Biroulet Laurent¹^ORCID

Affiliation:

1. Nancy University Hospital; Vandœuvre-lès-Nancy France

2. Imelda GI Clinical Research Centre; Bonheiden Belgium

3. Humanitas Clinical and Research Institute; Milan Italy

4. St Mark's Hospital; Middlesex London UK

5. Universidade Federal de São Paulo; São Paulo Brazil

6. Hospital São João; Porto Portugal

Funder

Pfizer

Celltrion Healthcare

Biogen

Sandoz

Samsung Bioepis

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15223/fullpdf

Reference50 articles.

1. Biosimilars in IBD: from theory to practice;Danese;Nat Rev Gastroenterol Hepatol,2017

2. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial;Jørgensen;Lancet,2017

3. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study;Yoo;Ann Rheum Dis,2017

4. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study;Park;Ann Rheum Dis,2017

5. The PROSIT-BIO Cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar;Fiorino;Inflamm Bowel Dis,2017

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review;BioDrugs;2024-06-15

2. Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study;Digestive and Liver Disease;2024-01

3. Patients’ Perceptions of Biosimilars: A Systematic Review;BioDrugs;2023-09-07

4. Clinical Outcomes and Patient Experience of Biosimilar to Biosimilar Infliximab Switching in Patients with Inflammatory Bowel Disease: A Prospective, Single-Centre, Phase IV Interventional Study with a Nested Qualitative Study;GastroHep;2023-08-25

5. Nocebo response intensity and influencing factors in the randomized clinical trials of functional dyspepsia: A systematic review and meta‐analysis;Journal of Digestive Diseases;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3